Oral Sialic Acid Product Beauty Efficacy Test

NCT07640321 | Completed

• 1 other identifier: SECCR/2022-132-01
• Study Type: observational
• Target: 83
• Locations: 1 country
• Sites: 1

Brief Summary

Evaluate and compare the effects on female facial skin of oral placebo (Product A), N-acetylneuraminic acid (Product B), and ACAI-PLUS (Product C) after 28, 56, and 84 days under normal usage conditions.

Conditions

Health Behavior

Outcome Measures

Primary Outcomes (1)

• Skin clinical scores

  Dermatologists use a 10-point scale (0-9) and Volume 2 of the Atlas of Skin Aging for visual/tactile assessment. (includes elasticity, firmness, crow's feet, under-eye wrinkles, facial sagging, skin tone radiance, moisturization)

  Day0、Day28、Day56、Day84

Secondary Outcomes (8)

• Self-assessment by subjects

  Day0、Day28、Day56、Day84

• Dermal echo parameters

  Day0、Day28、Day56、Day84

• Color and clarity of spots

  Day0、Day28、Day56、Day84

• Wrinkles, skin tone uniformity, and spots

  Day0、Day28、Day56、Day84

• Stratum corneum moisture index

  Day0、Day28、Day56、Day84

Study Arms (3)

Group A

placebo

Dietary Supplement: Oral placebo

Group B

N-acetylneuraminic acid

Dietary Supplement: Oral N-acetylneuraminic acid

Group C

ACAI-PLUS

Dietary Supplement: OralACAI-PLUS

Interventions

Oral placebo DIETARY_SUPPLEMENT

Oral placebo once daily for 84 consecutive days

Group A

Oral N-acetylneuraminic acid DIETARY_SUPPLEMENT

Oral N-acetylneuraminic acid, once daily, for 84 consecutive days

Group B

OralACAI-PLUS DIETARY_SUPPLEMENT

Oral ACAI-PLUS, once a day, for 84 consecutive days

Group C

Eligibility Criteria

• Age: 40 Years - 65 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Chinese Asian women aged 40-65, with facial skin issues such as pigmentation spots, lack of elasticity, and wrinkles

You may qualify if:

• Skin type origin: Asian in China
• Age: from 40 to 65 years old
• Gender: female
• Specific criteria:
• All skin type on the face Dry, dry combination, normal
• ≤ 6 according 10 points scale
• presenting with wrinkles on crow's feet area, grade ≥ 2 according to Skin ageing atlas Vol.2 (p.41)
• presenting with pigmentary spots with at least one with diameter ≥ 3mm
• Usual or occasional user of food supplements
• Able to give her informed consent

You may not qualify if:

• allergies or reactivity to cosmetic products,
• expectation of change in the current hormonal treatment during the study,
• having a chronic pathology,
• employee of the COSderma laboratory,
• pregnant or breast-feeding woman,
• woman not taking precaution to prevent pregnancy.
• cutaneous marks on the face which could interfere with the skin's clinical signs assessment (pigmentation issues, scar tissues, over-developed hairiness, too many ephelides and naevi, sunburns...),
• expectation or having undergone aesthetic or dermatological surgery on the face.

Sponsors & Collaborators

• Wuhan CASOV Green Biotech Co., Ltd: lead
• COSderma China Laboratory (Wuhan, China）: collaborator

Study Sites (1)

COSderma China Laboratory (Wuhan, China）

Wuhan, Hubei, 430071, China

Location

MeSH Terms

Conditions

Health Behavior

Interventions

N-Acetylneuraminic Acid

Condition Hierarchy (Ancestors)

Behavior

Intervention Hierarchy (Ancestors)

Sialic Acids; Neuraminic Acids; Sugar Acids; Acids, Acyclic; Carboxylic Acids; Organic Chemicals; Hydroxy Acids; Amino Sugars; Carbohydrates

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 2, 2026
• First Posted: June 10, 2026
• Study Start: September 25, 2023
• Primary Completion: December 22, 2023
• Study Completion: December 22, 2023
• Last Updated: June 10, 2026

Record last verified: 2026-06

Locations

CN (1)